GATC Health

GATC Health, a technology company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced that Gerald “Jerry” Sokol, Jr. has joined the company as Chief Administration Officer.

Jerry has extensive experience managing and growing both large and small companies in rapidly evolving environments. His expertise spans operations, sales and marketing, and finance across a wide variety of markets, including the U.S., Europe, China, Japan, Australia and Latin America. In his most recent role as Catalina Marketing’s Chief Executive Officer, Sokol was responsible for building a leading AI and data analytics product and reengineering Catalina’s digital product pipeline. As Amtrak’s Chief Financial Officer, Sokol was responsible for managing more than $11 billion in assets, $1.4 billion of debt, and a multi-billion-dollar operating budget. Previously, he was Chief Executive Officer of Vertis Communications, Inc., the third largest printing company in the U.S. with approximately $1.6 billion of annual revenue, printing free standing inserts, direct mail, large format as well as a newly created marketing services business which he successfully sold in 2013. He also spent 10 years at AOL, where he held numerous leadership roles, including Executive Vice President of AOL Access Operations as well as EVP of AOL’s International Operations and Strategy prior to his domestic responsibilities. At AOL, Jerry managed AOL’s international joint ventures and Domestic Access operations with experience ranging from overseeing product development, data analytics, and strategic alliances. Jerry began his career in the cable TV industry at Tele-Communications, Inc. and was involved in capital raising and mergers/acquisitions (including the creation of Liberty Media Corp).

“Jerry’s diverse experience when it comes to building transformative, technology centric businesses and, most importantly, hiring entrepreneurial executives to drive innovation and compete around the world make him the perfect choice for GATC Health’s CAO,” stated John Stroh, GATC Health's CEO. "He is a proven leader in creating shareholder value and will be instrumental as we build GATC Health for rapid growth."

"Being given the opportunity to work with a talented team who is dedicated to building the first-of-its-kind AI driven, predictive healthcare product is highly motivating,” stated Mr. Sokol. "I am inspired to join GATC as it transforms the pharmaceutical industry and enhances the doctor/patient relationship."

A Michigan native, Sokol received his master’s degree in finance from the University of Colorado, Denver. He earned a bachelor’s degree in finance at Oakland University in Rochester, Michigan.

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein

GATC Health, a technology company using advanced multiomic analysis and disruptive artificial intelligence to revolutionize disease detection and drug development, today announced that Darius Naigamwalla has joined the company’s Commercial Advisory Board. With executive management experience in biopharma, healthcare technology and medical devices, Mr. Naigamwalla will help GATC Health create and execute its corporate strategy, cementing its position as a leader in assisting biopharma organizations optimize their discovery and development efforts.

Mr. Naigamwalla brings over 20 years’ experience in biopharma services with Campbell Alliance, inVentiv Health (now Syneos), CEEK Enterprises, Two Labs and Envision Pharma Services. He has a broad range of therapeutic area experience covering oncology, immunology, cardiology, endocrinology, anti-infectives, dermatology, neurology and gastroenterology. During his career as a management consultant, Mr. Naigamwalla developed and led corporate strategy and implementation engagements for dozens of different biopharma companies resulting in substantial value creation.

“Darius’s biopharma experience and his track record in advising companies in creating value comes at a critical time for our company and our platform,” noted Jeff Moses, President of GATC Health. “He will be instrumental in both optimizing our business strategy and helping us build connections across the industry that will help maximize the potential of our platform and help realize the vision that GATC was built on: using advanced AI to detect diseases earlier and discover better drugs faster.”

Mr. Naigamwalla is currently an Executive Vice President at Two Labs Pharma Services, a leading pharmaceutical consulting company that provides corporate strategy, brand management, product launch, market access and market intelligence services, to manufacturers during the pre-launch period through to loss of exclusivity. Prior to being acquired by Two Labs, Mr. Naigamwalla was the President of CEEK Enterprises, a specialized management consultancy focused on biopharma and healthcare that he founded. He was previously a board member of Beacon Discovery, a world leader in GPCR-focused drug discovery and helped facilitate the sale of that business to Eurofins.

“I'm excited to have the opportunity to collaborate with GATC,” said Mr. Naigamwalla. “The platform technology is one of the best kept secrets in the industry with the potential to completely revolutionize drug discovery and development paradigms. It's time for this technology to shine.”

Disclaimer
The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities. This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained herein.